Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) cleared every item on its 2026 annual meeting ballot on September 9, 2026, with 94.53% of eligible shares represented. The case for a clean governance read is solid: both proposals passed and the board is intact. What complicates it is one directorial vote that drew considerably more opposition than the other two nominees on the same Class II slate.
Of 58,603,121 shares outstanding as of the July 17, 2026, record date, 55,399,491 were cast in person or by proxy at the Kirkland, Washington meeting. That participation rate stands out for an emerging growth company incorporated in Bermuda and listed on Nasdaq.
Three Class II directors were up for election. Raymond W. Cohen took 37,334,685 shares in favor and 10,779,640 against. Kevin Reilly drew 38,900,190 for and 9,204,737 against, while Traci S. Umberger drew 38,866,030 for and 9,238,943 against. The divergence between Cohen's against count and those of his two colleagues is the number in this filing worth studying. All three will serve until the company's 2029 annual general meeting. The 7,259,323 broker non-votes were identical across all three nominees, which limits the read-through: the Cohen gap was not broker-driven.
The second proposal ran in the other direction. Shareholders voted 55,356,225 in favor and only 8,469 against to ratify PricewaterhouseCoopers as Kestra's independent registered public accounting firm for the fiscal year ending April 30, 2027.
The counterargument matters here. Cohen was elected. The opposition never approached a threshold that would have blocked his seat, and the identical broker non-vote tally removes a clean structural explanation for the differential. His for-vote total was lower than either colleague's, but all three nominees faced the same pool of eligible votes on the same day.
On balance, this is a routine governance filing with one vote that runs against the grain. Brian Webster, President and Chief Executive Officer, signed the 8-K on September 10, 2026.